# reload+after+2024-01-23 08:44:34.418924
address1§500 Arsenal Street
city§Watertown
state§MA
zip§02472
country§United States
phone§617 607 0800
fax§617 607 0530
website§https://www.enanta.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
fullTimeEmployees§145
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Jay R. Luly Ph.D.', 'age': 67, 'title': 'President, CEO & Director', 'yearBorn': 1956, 'fiscalYear': 2022, 'totalPay': 1227506, 'exercisedValue': 460721, 'unexercisedValue': 10717033}, {'maxAge': 1, 'name': 'Mr. Paul J. Mellett Jr.', 'age': 68, 'title': 'Senior VP of Finance & Administration and CFO', 'yearBorn': 1955, 'fiscalYear': 2022, 'totalPay': 650936, 'exercisedValue': 100863, 'unexercisedValue': 2133748}, {'maxAge': 1, 'name': 'Dr. Yat Sun Or Ph.D.', 'age': 71, 'title': 'Senior VP of Research & Development and Chief Scientific Officer', 'yearBorn': 1952, 'fiscalYear': 2022, 'totalPay': 720163, 'exercisedValue': 0, 'unexercisedValue': 3573237}, {'maxAge': 1, 'name': 'Mr. Nathaniel S. Gardiner J.D.', 'age': 69, 'title': 'Senior VP, General Counsel & Secretary', 'yearBorn': 1954, 'fiscalYear': 2022, 'totalPay': 657949, 'exercisedValue': 0, 'unexercisedValue': 2323126}, {'maxAge': 1, 'name': 'Dr. Scott T. Rottinghaus M.D.', 'age': 49, 'title': 'Senior VP & Chief Medical Officer', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 616728, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Jennifer  Viera', 'title': 'Senior Director of Investor Relations & Corporate Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Tara Lynn Kieffer Ph.D.', 'age': 45, 'title': 'Senior Vice President of New Product Strategy & Development', 'yearBorn': 1978, 'fiscalYear': 2022, 'totalPay': 496852, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Brendan  Luu', 'age': 48, 'title': 'Senior Vice President of Business Development', 'yearBorn': 1975, 'fiscalYear': 2022, 'totalPay': 535805, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§4
boardRisk§4
compensationRisk§4
shareHolderRightsRisk§8
overallRisk§5
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.471
priceToSalesTrailing12Months§3.2198281
currency§USD
dateShortInterest§1702598400
forwardEps§-4.71
exchange§NMS
quoteType§EQUITY
shortName§Enanta Pharmaceuticals, Inc.
longName§Enanta Pharmaceuticals, Inc.
firstTradeDateEpochUtc§1363872600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§0716474a-69e6-3365-b278-ac9fe128aaa5
gmtOffSetMilliseconds§-18000000
targetHighPrice§40.0
targetLowPrice§12.0
targetMeanPrice§23.88
targetMedianPrice§22.0
recommendationMean§2.5
recommendationKey§buy
numberOfAnalystOpinions§8
quickRatio§6.522
grossMargins§1.0
ebitdaMargins§-1.70239
trailingPegRatio§None
